Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum
Background and purpose About a quarter of people with epilepsy have intellectual disability (ID). This group has communication issues, premature mortality, more treatment resistance, difficulties in making informed choices and greater risks of physical and mental health comorbidities. There is no sp...
Saved in:
Published in | European journal of neurology Vol. 23; no. 7; pp. 1152 - 1157 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.07.2016
John Wiley & Sons, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and purpose
About a quarter of people with epilepsy have intellectual disability (ID). This group has communication issues, premature mortality, more treatment resistance, difficulties in making informed choices and greater risks of physical and mental health comorbidities. There is no specific prescribing guidance for this large and vulnerable group. The literature on prescribing for epilepsy in this group was reviewed, in particular examining how antiepileptic drugs (AEDs) work regarding their side effect profiles, effects on specific epilepsy syndromes associated with ID and their individual strengths and weaknesses based on the nature and degree of ID.
Method
This is a narrative review for which a comprehensive search was conducted to identify evidence for prescribing commonly used AEDs to people with ID including genetic syndromes specifically associated with epilepsy.
Results
A detailed analysis of the results has highlighted the urgent requirement for suitable and reliable evidence in AED prescribing amongst adults with epilepsy and ID as no studies taking account of the response to AEDs of the ID populations based on the WHO Diagnostic and Statistical Manual of Mental Disorders criteria of clinical severity of ID were identified.
Conclusion
There is a significant shortfall in suitably powered studies to provide sufficient evidence for safe prescribing of AEDs to people with ID.
Click here to view the accompanying paper in this issue. |
---|---|
Bibliography: | Janssen-Cilag UCB Pharma ArticleID:ENE13016 Sanofi-Synthelabo Special Products Ltd Desitin Pfizer Eisai Data S1. The search strategy in detail.Data S2. A table of key papers and their findings.Data S3. Clinical Pearls for prescribing in ID. ark:/67375/WNG-8ZCJB9GV-F UCB istex:ED080FC93E7BE85630641BECAE16B02810E2BC25 GSK ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1351-5101 1468-1331 |
DOI: | 10.1111/ene.13016 |